June 1st 2024
Healthcare professionals who were aware of the safety and efficacy of biosimilars were more likely to prescribe or switch patients to a biosimilar.
Advancing Care in Erosive Esophagitis: Towards a Path of Complete Healing
View More
Shaping the Management of COPD with Biologic Therapy
View More
Elevating Care for PAH: Applying Recommended Management Approaches to Maximize Outcomes
View More
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Expert Illustrations & Commentaries™: Exploring the Role of Novel Agents for the Management of IgA Nephropathy
View More
Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies
View More
'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care
View More
A Tethered Approach to Type 2 Diabetes Care – Connecting Insulin Regimens with Digital Technology
View More
Patient, Provider & Caregiver Connection™: Implementing an Effective Management Plan to Improve Outcomes in IgA Nephropathy
View More
Originator Users in Finland Hesitant on Using Biosimilars
February 16th 2024Nearly half (47%) of biosimilar users knew they were using biosimilars but 31% thought the medicine was an originator. In contrast, 80% of originator users knew they were using an originator, and none thought they were using a biosimilar.
Biosimilars Month in Review: January 2024
The biosimilars month in review explores the efficacy and safety of biosimilars in treating uveitis, highlights the FDA’s acceptance of a biologics license application for an ustekinumab biosimilar, and emphasizes the safety and accessibility benefits of biosimilars in rheumatic conditions.
FDA Accepts Biologics License Application for Ustekinumab Biosimilar DMB-3115
BLA submission was based on data from phase 3 clinical trials in which DMB-3115 showed no clinically meaningful differences compared with the reference product for the treatment of plaque psoriasis.
Biosimilars Month in Review: December 2023
The biosimilars month in review highlights interviews with experts discussing the cost-saving potential of increased biosimilars uptake in the US, a recent US Food and Drug Administration (FDA) approval, and the impact of a mandatory switch to an adalimumab biosimilar in New Zealand.
Pooled Analysis Supports Bioequivalence Between MB02 and Reference Bevacizumab
December 5th 2023In a new pooled analysis of 3 pharmacokinetic studies, the investigators confirmed the bioequivalence, safety, and immunogenicity between biosimilar MB02 and European Union approved bevacizumab and US-approved bevacizumab.
Biosimilars Month in Review: November 2023
The biosimilars month in review highlights top data demonstrating the efficacy of biosimilars for treating inflammatory bowel disease and plaque psoriasis, as well as trends in adopting biosimilars among patients and clinicians in the US.
Study Compares Postoperative Thrombosis Incidence for Branded, Biosimilar Enoxaparin
December 5th 2023There was no statistically significant difference in postoperative thromboembolic events and incident heparin-induced thrombocytopenia among patients treated with branded versus biosimilar enoxaparin.